GlassScriptPhysician profile
Jennifer Huff
NPI 1649696949
$1,944.40
in general payments reported to CMS, 2019-2025
27 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $878 · 2022: $497 · 2023: $202 · 2024: $216 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $241.64 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $176.17 | 2023-2025 | |
| Incyte Corporation | $156.59 | 2021-2022 | |
| Janssen Biotech, INC. | $138.05 | 2021 | |
| Exelixis INC. | $121.82 | 2024 | Cabometyx |
| Puma Biotechnology, INC. | $113.10 | 2021-2023 | Nerlynx |
| Genentech USA, INC. | $97.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $97.22 | 2021-2022 | |
| Glaxosmithkline, LLC. | $88.55 | 2021-2022 | |
| Tempus Ai, INC | $72.72 | 2024 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $70.09 | 2021 | |
| Dendreon Pharmaceuticals LLC | $67.76 | 2025 | Provenge |
| Amgen INC. | $66.64 | 2021 | |
| Merck Sharp & Dohme LLC | $59.83 | 2021-2024 | Welireg, Keytruda |
| Novo Nordisk INC | $59.38 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $59.00 | 2022 | |
| Seagen INC. | $43.27 | 2021 | |
| Celgene Corporation | $34.91 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $30.64 | 2021-2022 | |
| Daiichi Sankyo INC. | $22.76 | 2021 | |
| Acceleron Pharma, INC. | $21.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.86 | 2021 | |
| Genzyme Corporation | $18.52 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.82 | 2021 | |
| Karyopharm Therapeutics INC. | $17.00 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.